ReviewDrugs2007
Crohn's disease: a review of current treatment with a focus on biologics.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 68 citations in OpenAlex.
- Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study.Frontiers in medicine · 2022Article
- Facing Terminal Ileitis: Going Beyond Crohn's Disease.Gastroenterology research · 2016Review
- Role of HLA typing on Crohn's disease pathogenesis.Annals of medicine and surgery (2012) · 2015Article
- Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review.American health & drug benefits · 2014Article
- Recent developments in the surgical management of perianal fistula for Crohn's disease.Annals of gastroenterology · 2014Review
- Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy.Dermatology and therapy · 2013Article
- A multidisciplinary team model of caring for patients with perianal Crohn's disease incorporating a literature review, topical therapy and personal practice.Frontline gastroenterology · 2013Article
- New era of biologic therapeutics in atopic dermatitis.Expert opinion on biological therapy · 2013Review
- Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment.Clinical rheumatology · 2012Article
- Inflammatory bowel disease: perioperative pharmacological considerations.Mayo Clinic proceedings · 2011Review
- Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.Drugs · 2010Review
- An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions.Irish journal of medical science · 2009Article
- Article
- Identification and characterization of kava-derived compounds mediating TNF-alpha suppression.Chemical biology & drug design · 2009Article
- Adalimumab for the treatment of Crohn's disease.Biologics : targets & therapy · 2008Article
- Stem cells as a potential future treatment of pediatric intestinal disorders.Journal of pediatric surgery · 2008Review
- Crohnology: a tale of time and times and inflammatory bowel diseases.World journal of gastroenterology · 2008Article
- Mucosal cytokine network in inflammatory bowel disease.World journal of gastroenterology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease is a debilitating and expensive disease that is growing in incidence in both developing and developed countries. While conventional therapies, such as corticosteroids and immunosuppressants, continue to play a vital role in treating this condition, it is evident that many affected individuals do not respond to therapy or develop intolerable adverse effects. The addition of modern biological therapies to the Crohn's disease armamentarium is providing a change in expectations for disease outcome. Infliximab and adalimumab are currently the only biological agents approved for induction and maintenance treatment in adults (infliximab and adalimumab) and children (infliximab) with Crohn's disease. Furthermore, infliximab has a beneficial effect on perianal fistulas. Other tumour necrosis factor (TNF)-alpha inhibitors, such as certolizumab pegol, also demonstrate promising results in adults with moderate to severe active disease. In addition, adalimumab and certolizumab pegol have shown clinical efficacy in patients who are intolerant to or lose response to infliximab, suggesting that switching between agents may allow response to be maintained over time. The primary safety concerns with TNFalpha inhibitors include increased risk of serious infection (including reactivation of tuberculosis), malignancy (particularly lymphoma) and demyelinating disease. Other agents in development include recombinant human anti-inflammatory cytokines, agents that target pro-inflammatory cytokines and granulocyte-macrophage colony-stimulating factors. Further prospective studies will provide interesting insight into different mechanisms by which factors involved in the pathophysiology of Crohn's disease can be modulated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.